Aquestive Therapeutics (AQST) shares rallied 14.8% in the last trading session to close at $5.67. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 26.3% gain over the past four weeks.The surge in stock price is likely due to positive expectations from investors regarding Aquestive’s regulatory filing, which seeks FDA approval for its key product candidate, Anaphylm, to treat severe allergic reactions. Earlier ...